Objective To assess the efficacy and safety of cetuximab in combination with cisplatin and 5-
fluorouracil for first-line treatment of Japanese patients with recurrent and/or metastatic …

Background The purpose of this study was to assess the efficacy, safety, and
pharmacokinetics of cisplatin‐based chemotherapy plus cetuximab as first‐line treatment in …

Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

Background The EXTREME regimen (chemotherapy [CT; cisplatin/carboplatin and 5-
fluorouracil]) plus cetuximab is a standard-of-care first-line (1L) treatment for patients with …

Background Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-
cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus …

Background The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F)
has previously been demonstrated to be effective in the treatment of metastatic squamous …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …

BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …

Background The efficacy and safety of a novel combination of weekly paclitaxel and the
epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …